The global professional services giant reported stronger-than-expected fourth-quarter results, with revenue climbing 8.7% to $6.60 billion. Strategic investments in digital infrastructure and artificial intelligence are credited for driving growth despite headwinds in insurance pricing.
As 2026 unfolds, the AI investment thesis is maturing beyond initial skepticism, creating opportunities in both leading tech giants and overlooked sectors. We analyze five companies, from semiconductor powerhouses to regional e-commerce leaders, positioned for a pivotal year.
Analyst firm Piper Sandler reiterates its Overweight rating on AGNC Investment Corp., highlighting a favorable shift in agency mortgage-backed securities spreads that could bolster the REIT's book value.
While homeownership is a common goal, the investment strategies of the affluent reveal a more nuanced picture. Analysis of wealth tiers shows real estate plays a varying, and often shrinking, role as net worth climbs into the millions.
After a punishing period, AGNC Investment Corp. staged a remarkable comeback in 2025. With a 12% dividend yield and a more favorable macroeconomic backdrop, the mortgage REIT is attracting income investors. But is the momentum sustainable?
PennyMac Mortgage Investment Trust (PMT) closed 2025 with robust earnings, driven by a dramatic expansion in its private-label securitization business. While this growth fueled returns, the company's correspondent lending segment faced pressure, and faster mortgage prepayments impacted servicing rights income.
PennyMac Mortgage Investment Trust (PMT) reported a robust fourth quarter, highlighted by a 13% return on equity and strategic advancements in its securitization business. Executives outlined a confident outlook for 2026, emphasizing disciplined risk management and growth in targeted lending segments.
Lockheed Martin capped a year of robust sales growth with a historic $194 billion order backlog, driven by soaring demand for its advanced defense systems. The aerospace giant announced plans for a significant 'step function' increase in capital investment for 2026 to ramp up production of missiles and next-generation capabilities.
As Sempra (NYSE: SRE) navigates a massive capital investment cycle for grid modernization and clean energy, investors are scrutinizing whether its current stock price accurately reflects its long-term strategy. We analyze key valuation metrics and the broader market context to assess if the utility giant is fairly valued.
With a cash reserve that could last just over a year at its current burn rate, InflaRx faces a critical period to prove its clinical pipeline's value. While management has reined in spending, the company's financial strategy is now under the microscope.
Exelixis shares have delivered impressive multi-year returns, but recent price weakness has investors questioning if the rally has run its course. A deep dive into valuation models suggests the stock may still be significantly undervalued, presenting a potential opportunity amidst market uncertainty.
Travere Therapeutics faces a securities fraud investigation by Robbins Geller Rudman & Dowd LLP, raising questions about the accuracy of its past disclosures. The probe casts a shadow over the company's critical transition, as it banks on its kidney drug FILSPARI to drive growth amid mounting legal and commercial pressures.
Investors face a classic choice between AbbVie's steady dividends and Abivax's high-risk, high-reward potential as both target lucrative immunology markets.
French biopharma firm Inventiva (ENXTPA:IVA) has delivered a stunning 126% total return to shareholders over the past year, sharply contrasting with losses over a three-year horizon. As the stock experiences short-term pullbacks, analysts debate whether its current €5.23 price reflects future promise or present hype, with a key drug candidate hanging in the balance.
Amidst recent market volatility driven by regional tensions, a closer look reveals companies with strong fundamentals demonstrating remarkable resilience and growth potential. We examine three such firms that are navigating the uncertainty and positioning themselves for the future.
Amidst the allure of high-growth tech narratives, Acsion (JSE:ACS) presents a case for steady, profitable growth. With strong insider alignment and improving margins, does this property-focused stock warrant a closer look from discerning investors?
As the pet care market expands, investors weigh the focused approach of Chewy against Walmart's diversified scale. While Chewy offers pure exposure, Walmart's broader ecosystem and advertising growth present a compelling alternative.
As Amgen prepares to release its fourth-quarter results, investors are watching for signs of sustained momentum in its key drug portfolios and the impact of recent acquisitions.
The Adecco Group's launch of a global HR and talent consulting platform under its LHH brand marks a deliberate shift towards higher-margin services. This analysis examines whether this strategic move can reshape the company's financial narrative amid ongoing margin pressures and a challenging debt profile.
In a significant move to bolster its healthcare services and retain staff, Walmart is creating thousands of new leadership positions and raising wages for pharmacy technicians across its U.S. stores.
